Vimarsana
Biggest News Aggregation in the World

Pascal Demoly News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pascal Demoly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pascal Demoly Today - Breaking & Trending Today

The Science of Sleep: 10-Year Study Unlocks the Secret to Overcoming Insomnia - Vimarsana News

The Science of Sleep: 10-Year Study Unlocks the Secret to Overcoming Insomnia

Consistently exercising 2-3 times a week over the long term is linked to a lower current risk of insomnia as well as the ability to clock up the recommended 6-9 hours of shut-eye every night, suggests an international 10-year study published in the open access journal BMJ Open. Regular exercise i

Sublingual Immunotherapy Stops Onset and Worsening of Asthma - Vimarsana News

Sublingual Immunotherapy Stops Onset and Worsening of Asthma

The French EfficAPSI study confirmed that sublingual liquid immunotherapy or "desensitization" reduces the risks for asthma onset and the worsening of asthma in patients with allergic rhinitis.

Allergists Seek to Improve Shot, Sublingual-Tablet Adherence - Vimarsana News

Allergists Seek to Improve Shot, Sublingual-Tablet Adherence

A review of published studies lists reasons why patients don't stick with allergy shots and sublingual immunotherapy, highlighting the need for careful consultation in choosing these treatments.

Stallergenes Greer: Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis - Vimarsana News

Stallergenes Greer: Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy